Company news

Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A (SSE:688192) news

Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: (688192)"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Voluntary…

Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A (SSE:688192) news

Press releases & updates

(688192)"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Receipt of a USD 600 Million Upfront Payment from AstraZeneca for the Global Licensing of ZEGFROVY

"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Use of Temporarily Idle Self-owned Funds for Entrusted Wealth Management

"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Shareholding Reduction Plan of Senior Executive

"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Publication of Research Results on Birelentinib for the Treatment of Diffuse Large B-Cell Lymphoma in "Blood Cancer Journal"

"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the Innovative Drug Industry

"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Shareholding Reduction Plan of Directors and Senior Management

"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Acceptance by the U.S. FDA of the Supplemental New Drug Application for Sunvozertinib as a Monotherapy for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026

"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 1st Meeting of the 3rd Board of Directors

"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Providing Guarantee for Controlled Subsidiary

"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026

"DIZAL PHARMACEUTICAL CO., LTD."Materials for the 2nd Extraordinary General Meeting in 2026

"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Abnormal Fluctuations in Stock Trading

"DIZAL PHARMACEUTICAL CO., LTD."Notice on Convening the 2nd Extraordinary General Meeting in 2026

Announcement on Voluntary Disclosure of Multiple Latest Research Advances in Lung Cancer at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer

Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Sunvozertinib as First-Line Monotherapy for EGFR Exon20ins Non-Small Cell Lung Cancer by the National Medical Products Administration and Its Inclusion in Priority Review

Announcement on Voluntary Disclosure of Study Results of the Hematological Tumor Products, Golidocitinib Birelentinib, Being Selected To Present at the 2026 Annual Meeting of the European Hematology Association (EHA)

Announcement on Change of Sponsor Representative for Continuous Supervision

Announcement on Participation in the "Dialogue on Growth" 2025 and Q1 2026 Collective Performance Briefing

Report for Q1 2026

Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference

Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on the 2nd Vesting Results in the 3rd Vesting Period for Category I Incentive Objects of Those Initially Granted in the 2022 Restricted Stock Incentive Plan and Stock Listing

2025 Annual Report

Announcement on Voluntary Disclosure of the Latest Data of Suvozertinib as First-Line Treatment for EGFR PACC or Other Rare Mutant Non-Small Cell Lung Cancer Released at the 2026 European Lung Cancer Conference (ELCC)

Announcement on Voluntary Disclosure of Positive Top-line Results from the International Multicenter Phase III Clinical Trial of Shuvozhe Monotherapy as First-line Treatment for EGFR exon20ins Non-small Cell Lung Cancer

Announcement on Early Return of Idle Raised Funds for Temporary Supplementary Working Capital

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Listing and Circulation of Shares from the 2nd Exercise Window of the 2nd Exercise Period under the 2020 Employee Stock Option Plan

Announcement on the Results of the Partial Vesting of the 2nd Vesting Period for the Second Category of Incentive Recipients under the Initial Grant, Partial Vesting of the 1st Vesting Period for the Reserved Grant Objects under the 2022 Restricted Stock Incentive Plan, and Stock Listing

Announcement on Changing English Name of the Company, Amending the "Articles of Association", and Handling Industrial and Commercial Change Registration

Announcement on Expected Loss in Performance for 2025

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Announcement on Resolutions of the 18th Meeting of the 2nd Board of Directors

Announcement on the Resignation of Independent Directors

Announcement on Changing Registered Capital, Amending the Articles of Association, and Handling Industrial and Commercial Change Registration

Announcement on Listing and Circulation of Shares from the 1st Exercise Window of the 2nd Exercise Period under the 2020 Employee Stock Option Plan

Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025

Announcement on Election of Employee Director

Announcement on Vesting Results in the 2nd Vesting Period for Category I Incentive Objects of Those Initially Granted in the 2022 Restricted Stock Incentive Plan and Stock Listing

Announcement on Voluntary Disclosure of Information Regarding Multiple Studies on Golidocitinib (Gaoruize) and Birelentinib Included in the 67th Annual Meeting of the American Society of Clinical Hematology (ASH)

Announcement on Initial Public Offering of Temporarily Idle Raised Funds for Cash Management

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on Circulation of Restricted Shares Issued to Specific Objects

Announcement on Release of Multiple Latest Research Results in the Field of Lung Cancer by the Company at the 2025 World Conference on Lung Cancer (WCLC)